What is AbCellera Biologics Inc.'s revenue?

AbCellera Biologics Inc. (ABCL) generated $79.2M in revenue over the trailing twelve months, up 242.7% year over year.

Is AbCellera Biologics Inc. profitable?

AbCellera Biologics Inc. is not currently profitable: it reported a net loss of $144.0M over the trailing twelve months, a -181.7% net margin.

What is AbCellera Biologics Inc.'s earnings per share?

AbCellera Biologics Inc.'s diluted EPS over the trailing twelve months is $-0.48.

Where does AbCellera Biologics Inc.'s income statement data come from?

Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

AbCellera Biologics Inc. ABCL Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$79.21M+243%	$75.13M+161%	$35.32M+7.2%	$32.88M-0.5%	$23.12M-35.4%
Research and development	$191M+12.0%	$186.83M+11.7%	$182.81M+7.7%	$168.75M+1.2%	$170.47M+5.0%
Selling, general and administrative	——	——	——	——	——
Compensation and benefits	$53.02M-18.4%	$55.79M-17.4%	$58.11M-15.5%	$61.38M-9.1%	$64.96M-1.8%
Occupancy and equipment	——	$11.3M+24.2%	$10.75M+16.8%	$10.2M+9.7%	$9.65M+2.7%
Depreciation and amortization	——	——	——	——	——
Other operating expenses	$291.17M-15.8%	$292.23M-14.9%	$296.6M-13.0%	$311.54M+3.0%	$345.65M+31.4%
Total operating expenses	$291.17M-15.8%	$292.23M-14.9%	$296.6M-13.0%	$311.54M+3.0%	$345.65M+31.4%
Operating income	-$211.96M+34.3%	-$217.11M+31.0%	-$261.28M+15.2%	-$278.66M-3.5%	-$322.53M-41.9%
Operating margin	-267.6%+1,128pp	-289%+803pp	-739.7%+195pp	-847.6%-32.9pp	-1,395.3%-760pp
Interest income	$23.92M-28.8%	$25.8M-32.9%	$28.55M-30.0%	$31.39M-25.1%	$33.6M-21.7%
Other income (expense), net	$37.82M-66.2%	$39.51M-65.5%	$56.35M-46.8%	$79.87M-11.7%	$111.9M+91.0%
Income before income taxes	-$174.15M+17.3%	-$177.6M+11.4%	-$204.93M-1.4%	-$198.79M-11.2%	-$210.63M-24.9%
Income tax expense	-$30.19M+29.4%	-$31.18M+16.9%	-$33.25M-26.1%	-$33.12M-29.8%	-$42.76M-96.8%
Net income	-$143.96M+14.2%	-$146.41M+10.1%	-$171.68M+2.3%	-$165.67M-8.1%	-$167.87M-14.3%
Net margin	-181.7%+544pp	-194.9%+370pp	-486%+47.3pp	-503.9%-40.1pp	-726.2%-316pp
Preferred stock dividends	——	$0—	——	——	——
Diluted earnings per share	-$0.48+14.3%	-$0.49+10.9%	-$0.57+6.6%	-$0.55-1.9%	-$0.56-7.7%
Basic earnings per share	-$0.48+14.3%	-$0.49+10.9%	-$0.57+6.6%	-$0.55-1.9%	-$0.56-7.7%
Weighted-average shares, diluted	1.2B+1.5%	1.2B+1.5%	1.2B+1.6%	1.2B+1.7%	1.2B+1.8%
Weighted-average shares, basic	1.2B+1.5%	1.2B+1.5%	1.2B+1.6%	1.2B+1.7%	1.2B+1.8%
Share-based compensation expense related to employee stock plans	$53.31M-18.2%	$56.28M-16.7%	$58.63M-14.8%	$61.79M-8.5%	$65.16M-1.5%
Pre-tax stock-based compensation cost	$53.02M-18.4%	$55.79M-17.4%	$58.11M-15.5%	$61.38M-9.1%	$64.96M-1.8%
Amortization of capitalized software and acquired intangible assets	$3.7M—	$3.7M—	——	——	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	292.5M+18.5%	285.3M+22.0%	272.6M+20.8%	260M+19.4%	246.8M+17.5%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	-$43.48M+5.0%	-$55.88M-77.8%	$35.69M+151%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$139.38M+19.5%	-$146.27M+11.6%	-$173.14M+1.4%	-$166.25M-8.3%	-$173.05M-18.0%
Revenue recognized that was included in deferred income at the beginning of the period	$22.9M+56.8%	$17.6M-14.6%	$17M-31.7%	$14.3M-38.1%	$14.6M-35.7%
Federal	——	-$30.04M-62.8%	-$27.15M-27.8%	-$24.25M-0.9%	-$21.36M+20.3%
Foreign	——	-$201K-130%	$17K-96.6%	$235K-30.0%	$453K+170%
Deferred tax expense (recovery)	——	-$938K+95.3%	-$5.64M+60.6%	-$10.34M-16.3%	-$15.05M-334%
Federal	——	$0-100%	$187.25K-88.9%	$374.5K-85.8%	$561.75K-84.3%
Deferred Foreign Income Tax Expense Benefit	——	-$938K+95.4%	-$5.83M+63.6%	-$10.72M+7.1%	-$15.61M-121%
Depreciation	$19.9M+45.2%	$18.39M+47.7%	$15.31M+7.5%	$14.81M+9.4%	$13.71M+4.3%
Dividends Cash	——	$0—	——	——	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——	——
Effective tax rates	——	$0.18—	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Capital treatment of items	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Gain on contingent consideration	——	——	——	——	——
Share-based compensation	——	——	——	——	——
Provincial taxes net of Federal benefit	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Provincial Taxes Federal Benefit, Amount	——	$1.13M—	——	——	——
Excess tax benefits associated with employee equity plans	——	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——	——
Distributions of earnings from equity method investees	——	$30.11M—	$22.58M—	$15.06M—	$7.53M—
Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount	——	$200K-98.8%	$4.3M-66.7%	$8.4M-8.7%	$12.5M+127%
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	——	$200K-98.8%	$4.3M-66.7%	$8.4M-8.7%	$12.5M+127%
Gain (Loss) on Contingent Consideration and Investments	——	-$4.53M-107%	$12.79M-74.7%	$30.1M-17.2%	$47.41M+114%
Non-cash financing activities	$11.13M—	$8.3M—	——	——	——
Non-cash investing activities	$800K—	$800K—	——	——	——
Grants And Incentives	$14.08M-2.9%	$13.89M+2.0%	$14.12M+5.0%	$14.88M+16.3%	$14.5M+3.2%
Income Loss From Continuing Operations Before Income Taxes Domestic	——	-$188.46M+0.5%	-$188.72M-5.6%	-$188.97M-12.5%	-$189.22M-20.4%
Income Loss From Continuing Operations Before Income Taxes Foreign	——	$10.87M+200%	$5.42M+136%	-$27K+99.9%	-$5.47M+76.7%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$12.32M-19.0%	$13.04M-8.6%	$13.76M+3.1%	$14.48M+16.7%
Income Tax Reconciliation Change In Tax Rate Differential	——	——	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	——	——	——	——
Share-based compensation	——	$11.86M—	——	——	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	——	$252K+227%	$208.25K+608%	$164.5K+203%	$120.75K+144%
Income Tax Reconciliation Prior Year Income Taxes	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	——	$6M-27.0%	$6.56M-18.3%	$7.11M-9.1%	$7.67M+0.5%
Accounts payable and other current liabilities	-$2.54M-121%	$3.46M-67.5%	$4.33M+1,690%	$3.41M+144%	$12.1M+175%
Increase Decrease In Accrued Income Taxes Payable	-$30.41M-660%	-$29.84M-549%	-$4.43M+36.0%	$5.02M+208%	$5.43M-86.4%
Increase Decrease In Deferred Grant Income	$4.77M+122%	$3.64M+111%	-$462K+98.8%	-$12.53M+62.8%	-$21.47M+53.6%
Deferred revenue	——	——	——	——	——
Increase (Decrease) in Other Operating Assets	-$8.09M+52.1%	-$17.15M-188%	-$19.02M-27.3%	-$20.88M+3.4%	-$16.88M+18.5%
Increase Decrease In Receivables	$41.39M-28.2%	$55.62M-26.0%	$36.82M-43.1%	$53.21M-5.1%	$57.68M-20.4%
Marketable Securities Unrealized Gain Loss	——	$800K0.0%	$800K-28.9%	$800K-44.8%	$800K-54.9%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——	——	——	——	$15.91M+16.6%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$54.73M-45.0%	$87.75M-27.7%	$48.32M-21.3%	$15.53M-65.4%	$99.43M+339%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$153.26M-95.5%	-$131.3M-20.9%	-$104.55M+13.0%	-$80.84M+11.5%	-$78.4M—
Property and equipment in accounts payable	——	——	——	——	——
Right-of-use assets obtained in exchange for operating lease obligation	$72.76M—	$76.12M—	——	——	——
Number of joint ventures	——	——	——	——	——
Number of operating segments	——	1—	——	——	——
Number of reportable segments	——	1—	——	——	——
Occupancy and Related Charges	——	$11.3M+24.2%	$10.75M+16.8%	$10.2M+9.7%	$9.65M+2.7%
Operating lease right-of-use assets amortization expense	$7.19M+30.8%	$6.65M+8.1%	$6.19M-3.1%	$5.58M-16.6%	$5.5M-19.3%
Foreign currency translation	——	——	-$1.47M-743%	-$584K-236%	-$5.18M-2,628%
Other Noncash Income (Expense)	$3.17M—	$3.33M—	——	——	——
Payments for (Proceeds from) Loans Receivable	——	-$33.27M—	-$24.95M—	-$16.63M—	-$8.32M—
Payments to Acquire Marketable Securities	$437.36M-35.7%	$436.04M-43.0%	$477.54M-46.3%	$630.62M-31.4%	$680.71M-25.2%
Payments To Acquire (Proceeds from) Long Term Investments And Other Assets	$9.71M—	$17.09M—	——	——	——
Payments to Acquire Property, Plant, and Equipment	$35.97M-44.6%	$42.77M-45.4%	$48.56M-37.1%	$58.15M-26.4%	$64.89M-24.6%
Proceeds from legal settlements	——	——	——	——	——
Proceeds from long-term liabilities and other	——	$29.73M+120%	$25.67M+97.2%	$21.61M+72.3%	$17.56M+45.5%
Proceeds from long-term liabilities and other	——	——	——	——	——
Receipt of grant funding	$21.69M-26.6%	$21.34M-40.2%	$13.92M-64.7%	$22.41M-40.0%	$29.56M-0.8%
Proceeds from maturities of marketable securities	$459.85M-44.0%	$506.07M-46.0%	$588.43M-41.4%	$701.93M-31.7%	$821.36M-14.0%
Revenue From Contract With Customer Excluding Assessed Tax	$79.21M+243%	$75.13M+161%	$35.32M+7.2%	$32.88M-0.5%	$23.12M-35.4%
Stock-based compensation	$53.02M-18.4%	$55.79M-17.4%	$58.11M-15.5%	$61.38M-9.1%	$64.96M-1.8%
Shares issued and restricted stock units (“RSUs”) vested under stock option plan	$1.17M+22.1%	$806K-52.6%	$458K-78.0%	$572K-72.9%	$959K-51.7%
Variable lease payments	——	$500K-28.6%	$550K-31.3%	$600K-33.3%	$650K-35.0%
EBIT	-$211.96M+34.3%	-$217.11M+31.0%	-$261.28M+15.2%	-$278.66M-3.5%	-$322.53M-41.9%
EBITDA	-$188.32M+22.1%	-$194.97M+16.8%	-$243.13M-9.4%	-$228.84M-6.6%	-$241.66M-18.8%
EBITDA	-$188.32M+22.1%	-$194.97M+16.8%	-$243.13M-9.4%	-$228.84M-6.6%	-$241.66M-18.8%
EBITDA margin	-237.8%+808pp	-259.5%+553pp	-688.3%-14.1pp	-696.1%-46.7pp	-1,045.5%-477pp
EBIT	-$211.96M+34.3%	-$217.11M+31.0%	-$261.28M+15.2%	-$278.66M-3.5%	-$322.53M-41.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about AbCellera Biologics Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s revenue?: AbCellera Biologics Inc. (ABCL) generated $79.2M in revenue over the trailing twelve months, up 242.7% year over year.
Is AbCellera Biologics Inc. profitable?: AbCellera Biologics Inc. is not currently profitable: it reported a net loss of $144.0M over the trailing twelve months, a -181.7% net margin.
What is AbCellera Biologics Inc.'s earnings per share?: AbCellera Biologics Inc.'s diluted EPS over the trailing twelve months is $-0.48.
Where does AbCellera Biologics Inc.'s income statement data come from?: Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.